News & Updates
Filter by Specialty:
Polycythemia ups risk of MACE, VTE in men on testosterone therapy
Men receiving testosterone therapy (TT) who develop polycythemia are at greater risk for major adverse cardiovascular events (MACE) and venous thromboembolism (VTE) in the first year of therapy, according to a recent study.
Polycythemia ups risk of MACE, VTE in men on testosterone therapy
06 Jun 2022
Whole pelvic radiation therapy improves survival in high-risk prostate cancer
Prostate cancer (PCa) patients with higher lymph node (LN) risk scores and Gleason grade who are treated with whole pelvis radiotherapy (WPRT) have better overall survival (OS), reports a study.
Whole pelvic radiation therapy improves survival in high-risk prostate cancer
02 Jun 2022
Chemoradiotherapy improves disease control in muscle-invasive bladder cancer
Chemotherapy with 5-fluorouracil (5FU) and mitomycin C (MMC), when combined with radiotherapy, leads to better locoregional control over a 10-year window in patients with muscle-invasive bladder cancer (MIBC), a recent study has found.
Chemoradiotherapy improves disease control in muscle-invasive bladder cancer
28 May 2022
Short-course IV antibiotics should be considered for nonbacteraemic UTI in babies
In the treatment of young infants with nonbacteraemic urinary tract infection (UTI), administering intravenous (IV) antibiotics for less than 48 hours appears to work well in the absence of meningitis, with low rates of treatment failure and serious complications, according to a study.
Short-course IV antibiotics should be considered for nonbacteraemic UTI in babies
18 May 2022
Pelvic floor muscle exercises beneficial in postprostatectomy urinary incontinence
Pelvic floor muscle exercises appear to exert favourable effects on urinary incontinence in men who have undergone prostate cancer surgery, according to a study.
Pelvic floor muscle exercises beneficial in postprostatectomy urinary incontinence
17 May 2022
Oral tebipenem pivoxil hydrobromide works against complicated UTI, acute pyelonephritis
Oral tebipenem pivoxil hydrobromide appears to be as good as intravenous ertapenem in the treatment of patients with complicated urinary tract infection (UTI) and acute pyelonephritis, with the two having a similar safety profile, according to data from a phase III study.